EANS-News: Announcement according to § 93 of the Austrian Stock Exchange Act
Vienna, December 30, 2009 (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Capital measures
Following the completion of a capital increase of 900,000 shares, which were sold to GlaxoSmithKline Biologicals SA at an issue price of EUR 31.21 per share, and admission of the new shares for trading on the Official Market of the Vienna Stock Exchange, Intercell AG, with its principal offices in Vienna, makes the following announcement required under Austrian law regarding changes in voting rights:
Announcement of the total number of voting rights according to section 93 subsection 1 of the Austrian Stock Exchange Act: The total number of shares of common stock with no par value of Intercell AG, each representing one vote, has increased to 48,480,486. The share capital is now EUR 48,480,486.-.
Announcement of Novartis Pharma AG´s share in voting rights according to section 93 subsection 2 of the Austrian Stock Exchange Act:
Due to the dilution through the capital increase of Intercell AG of EUR 900,000 the interest in shares with voting rights of Novartis Pharma AG has fallen below the threshold of 15% as of 30 December 2009. Novartis Pharma AG still holds 7,244,940 shares with voting rights in Intercell AG, currently representing 14.9% of the voting rights.
The Management Board
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market